Fatima Fatima Abdurrazaq

Mrs. Fatima Fatima Abdurrazaq

orcid

Research Focus & Metrics

Academic Career Length

1Year (2026-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
10 November 2026 in Chemistry Proceedings
Verified
Conference Paper
Open access
PDF file
FAFatima Fatima Abdurrazaq
Fatima Fatima Abdurrazaq
EOEnayi Onaji
Enayi Onaji
AYAbubakar Sadiq Yakubu
Abubakar Sadiq Yakubu
AHAsmau Nasiru Hamza
Asmau Nasiru Hamza
Diabetes mellitus is a major global public health challenge associated with significant morbidity and mortality. Although α-glucosidase inhibitors are widely used in the management of postprandial hyperglycemia, currently available drugs are often associated with undesirable side effects, reduced patient compliance, and limited therapeutic effectiveness. Consequently, there is a growing need to identify novel inhibitors with improved efficacy and safety profiles. This study aimed to investigate the potential of 14 chalcone and 4 pyrazoline compounds (18 compounds in total) as potential α-glucosidase inhibitors using computational approaches. A library of compounds was designed using ChemDraw and subjected to geometry optimization with Spartan14 software. Drug-likeness, pharmacokinetic, and toxicity properties were assessed using SwissADME and ProTox-II servers. Molecular docking studies were performed against the α-glucosidase enzyme (PDB ID: 8YIE) using AutoDock Vina to determine binding affinities and interactions within the enzyme’s active site. ADMET analysis revealed that the majority of the compounds exhibited favorable pharmacokinetic characteristics and acceptable safety profiles. Among the screened compounds, compounds PC1 and PHPY exhibited the most favorable docking scores at −9.8 kcal/mol and −9.3 kcal/mol, respectively, surpassing the reference ligand acabose (AC1) (−8.8 kcal/mol). Detailed interaction analysis revealed the formation of key hydrogen bonds, π–π stacking, and π–alkyl interactions with critical active-site residues. These findings suggest that the investigated chalcone and pyrazoline compounds may be promising candidates for further investigation as potential α-glucosidase inhibitors. However experimental enzyme inhibition assays and appropriate safety studies are necessary to validate their predicted biological activity and establish their safety profiles.